InMed Pharmaceuticals Inc. (INM) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
Address
815 West Hastings Street
Vancouver, BC V6C 1B4
Canada
Phone
604 669 7207
Website
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
May 05, 2014
| Name | Title | Pay | Year Born |
| Eric A. Adams Chem. | President, Chief Executive Officer & Director | 377,129 | 1964 |
| Sazzad Hossain | Co-Founder | 130,601 | 1958 |
| N. Netta Jagpal | Chief Financial Officer & Corporate Secretary | 291,813 | 1973 |
| Eric Chih-Hsien Hsu | Senior Vice President of Preclinical Research & Development | 314,891 | 1971 |
| Michael Woudenberg | Chief Operating Officer | 335,216 | 1970 |
| Shane A. Johnson | Senior Vice President & GM of BayMedica | 0 | N/A |
| Colin Clancy | VP of Investor Relations & Corporate Communications | 0 | N/A |
| Jerry Griffin | Vice President of Sales & Marketing | 0 | N/A |
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.